---
title: "Descartes-08 in Generalized myasthenia gravis: Complement c5 inhibitors"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Complement c5 inhibitors. Topics: Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update; Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance; Eculizumab: FDA-labeled indication, dosing, and pivotal trial; Eculizumab biosimilars: FDA-labeled indication; 9 further topics. 13 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/complement-c5-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Complement c5 inhibitors

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Complement C5 Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

### Eculizumab in refractory AChR antibody-positive disease: 2020 consensus update

> “In a phase III international multicenter RCT of 125 patients with refractory generalized nonthymomatous AChR-Ab+ MG (REGAIN), the primary outcome measure of change in the MG-ADL score from baseline to week 26, measured by worst-rank analysis of covariance, was not significantly different ( p = 0.0698) between eculizumab and placebo arms.”
> “Eculizumab should be considered in the treatment of severe, refractory, AChR-Ab+ generalized MG (median 9, range 2–9). The role of eculizumab in the treatment of MG is likely to evolve over time. Until further data become available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals (median 9, range 5–9).”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.1.6-2"></a>

### Complement inhibitors and FcRn blockers as second-line treatments: Nordic guidance

> “Several inhibitors of complement proteins have appeared within the last 5 years as a new treatment modality for refractory or difficult‐to‐treat MG patients”
> “The treatment effect is seen within the first 2 weeks and maximal effect appears within the first 2 months.”
> “Due to high drug costs, complement and FcRn inhibitors are recommended only for difficult‐to‐treat patients with severe MG not responding to standard immunosuppressive treatment. Complement and FcRn inhibitors act fast, have a proven effect with an acceptable safety profile, with a selective impact on the immune system. If costs permit and are acceptable, they should be recommended as alternative second‐line treatments.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.6-3"></a>

### Eculizumab: FDA-labeled indication, dosing, and pivotal trial

> “900 mg weekly for the first 4 weeks, followed by • 1,200 mg for the fifth dose 1 week later, then • 1,200 mg every 2 weeks thereafter.”
> “A statistically significant difference favoring SOLIRIS was observed in the mean change from baseline to Week 26 in MG-ADL total scores [-4.2 points in the SOLIRIS-treated group compared with -2.3 points in the placebo-treated group (p=0.006)].”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-2.2.2.1.6-4"></a>

### Eculizumab biosimilars: FDA-labeled indication

> “The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Source: [Bkemv prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761333s008lbl.pdf)

> “the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”

Source: [Epysqli prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761340s024lbl.pdf)

<a id="topic-2.2.2.1.6-5"></a>

### Ravulizumab: FDA-labeled indication, dosing, and pivotal trial

> “with maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.”
> “Patients were randomized 1:1 to either receive ULTOMIRIS (n=86) or placebo (n=89) for 26 weeks.”
> “Treatment with ULTOMIRIS demonstrated a statistically significant change in the MG-ADL and QMG total scores from baseline at Week 26 as compared to placebo”
> “Primary Endpoint MG-ADL -1.4 -3.1 -1.6 (-2.6, -0.7) < 0.001”

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

### Zilucoplan: FDA-labeled indication, dosing, and pivotal trial

> “ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.”
> “A total of 174 patients were enrolled in Study 1 and were randomized 1:1 to receive either ZILBRYSQ 0.3 mg/kg (n=86) or placebo (n=88) once daily by subcutaneous injection.”
> “At week 12, treatment with ZILBRYSQ demonstrated a statistically significant improvement from baseline compared to placebo for MG-ADL total score and QMG total score”
> “MG-ADL Total Score -4.39 (-5.28, -3.50) -2.30 (-3.17, -1.43) -2.09 (-3.24, -0.95) < 0.001”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

### Target of approved complement inhibitors

> “To date, all FDA-approved drugs in this category focus on targeting the C5 convertase enzyme.”
> “Zilucoplan is a small macrocyclic peptide that not only binds to C5 to inhibit its cleavage, but also interferes with C5b binding to C6.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.6-8"></a>

### Eculizumab: REGAIN phase 3 trial in refractory AChR antibody-positive disease, 26 weeks

> “Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control.”
> “Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698).”
> “Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy.”
> “The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed.”

Source: [Howard et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29066163/)

<a id="topic-2.2.2.1.6-9"></a>

### Ravulizumab: CHAMPION MG phase 3 trial, 26 weeks

> “In this randomized, double-blind, placebo-controlled, multinational trial, we randomly assigned (1:1) patients with anti-AChR antibody-positive gMG to intravenous ravulizumab or placebo for 26 weeks.”
> “In total, 175 patients were enrolled. Ravulizumab significantly increased the magnitude of mean changes from baseline to week 26 versus placebo in MG-ADL (−3.1 vs. −1.4; P<0.001) and QMG (−2.8 vs. −0.8; P<0.001) total scores.”
> “QMG total scores improved by 5 points or more in a significantly greater proportion of ravulizumab-treated patients than of those receiving placebo (30.0% vs. 11.3%; P=0.005).”

Source: [Vu et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319212/)

<a id="topic-2.2.2.1.6-10"></a>

### Zilucoplan: RAISE phase 3 trial, modified intention-to-treat population, 12 weeks

> “Between Sept 17, 2019, and Sept 10, 2021, 239 patients were screened for the study, of whom 174 (73%) were eligible. 86 (49%) patients were randomly assigned to zilucoplan 0·3 mg/kg and 88 (51%) were assigned to placebo.”
> “Patients assigned to zilucoplan showed a greater reduction in MG-ADL score from baseline to week 12, compared with those assigned to placebo (least squares mean change -4·39 [95% CI -5·28 to -3·50] vs -2·30 [-3·17 to -1·43]; least squares mean difference -2·09 [-3·24 to -0·95]; p=0·0004).”
> “TEAEs occurred in 66 (77%) patients in the zilucoplan group and in 62 (70%) patients in the placebo group. The most common TEAE was injection-site bruising (n=14 [16%] in the zilucoplan group and n=8 [9%] in the placebo group).”

Source: [Howard et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37059508/)

<a id="topic-2.2.2.1.6-11"></a>

### Gefurulimab: FDA-labeled mechanism, pivotal trial responder rates, and adverse reactions

> “Gefurulimab-gaks binding to C5 inhibits its cleavage to C5a and C5b thus preventing the formation and deposition of membrane attack complex (MAC or C5b-9) at the neuromuscular junction.”
> “Patients were randomized 1:1 to either receive KLYGEFA (n=131) or placebo (n=129) for 26 weeks.”
> “The proportion of MG-ADL responders with at least a 3-point improvement at Week 26 was greater for KLYGEFA (65.5%) compared to placebo (52.2%), p = 0.037. The proportion of QMG responders with at least a 5-point improvement at Week 26 was greater for KLYGEFA (46.3%) compared to placebo (25.2%), p = 0.002.”
> “The most common adverse reactions in the gMG placebo-controlled clinical study (at least 10%) were injection site reactions.”

Source: [Klygefa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761488s000lbl.pdf)

<a id="topic-2.2.2.1.6-12"></a>

### Gefurulimab: PREVAIL phase 3 trial, 26 weeks

> “This randomized clinical trial, PREVAIL, was a phase 3, double-blind, placebo-controlled study conducted at 113 sites in 20 countries.”
> “Of 405 patients screened, 145 were excluded; 260 met eligibility criteria and were randomized (gefurulimab, n = 131; placebo, n = 129); 249 patients completed the 26-week randomized controlled treatment period.”
> “Least-squares mean change from baseline at week 26 for MG-ADL and QMG total scores for gefurulimab vs placebo were −4.2 vs −2.6 (treatment difference, −1.6; 95% CI, −2.4 to −0.8; P < .001) and −4.5 vs −2.4 (treatment difference, −2.1; 95% CI, −3.1 to −1.1; P < .001), respectively.”
> “The incidence of adverse events (AEs) was similar between groups. Most common treatment-emergent AEs with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported.”

Source: [Gwathmey et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13409125/)

<a id="topic-2.2.2.1.6-13"></a>

### Complement C5 inhibitor initiation, monotherapy, and response assessment: German-Austrian expert recommendations

> “Recommendation (consensus): Add‐on therapy with C5‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR autoantibodies.”
> “Recommendation (consensus): The use of C5‐I as monotherapy should be considered only in exceptional cases, for example, when standard immunotherapies are ineffective, associated with intolerable AEs, or contraindicated, including in the context of chronic infection or malignancy.”
> “Recommendation (strong consensus): Treatment response should be assessed after 12 weeks of C5‐I therapy, as clinical response or non‐response can usually be determined by this time and used to guide further treatment planning.”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
